<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973725</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-29</org_study_id>
    <nct_id>NCT01973725</nct_id>
  </id_info>
  <brief_title>Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy</brief_title>
  <official_title>PhaseⅡ Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhong Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic&#xD;
      Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently,there is no standard second-line therapy for esophageal squamous cell&#xD;
      carcinoma.More effective therapy for patients with this disease who developed disease&#xD;
      progression after first line therapy is needed.Although Erlotinib is recommended in NCCN&#xD;
      Guideline Version 2.2013,there is still insufficient evidence on EGFR-TKI as second-line&#xD;
      therapy for esophageal squamous carcinoma.Therefore,further research is necessary.In this&#xD;
      phase II study,we evaluate the efficacy and safety of Icotinib Hydrochloride as treatment for&#xD;
      patients with recurrent or metastasis esophageal squamous carcinoma after failure of&#xD;
      conventional chemotherapy,and analyse the value of biomarkers of these patient to identify&#xD;
      who benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from day 1 to date of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time from day 1 to date of documented disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Each follow up vist, assessed up to 12 months</time_frame>
    <description>Safety data will be assessed at each study visit using NCI CTCAE version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Time from day 1 to date of death</time_frame>
    <description>Quality of life will be assessed at each study visit using EORTC QLQ-C30 and QLQ-OES18</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Icotinib Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib Hydrochloride</intervention_name>
    <description>Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.</description>
    <arm_group_label>Icotinib Hydrochloride</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have provided a signed Informed Consent Form&#xD;
&#xD;
          -  Age: 18-75 years old&#xD;
&#xD;
          -  Histologically confirmed diagnosis of esophageal squamous cell carcinoma&#xD;
&#xD;
          -  Patients have Received and progressed on 1 line of prior Fluoropyrimidine, platinum or&#xD;
             taxane based palliative chemotherapy&#xD;
&#xD;
          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Karnofsky score ≥70&#xD;
&#xD;
          -  Patient has adequate bone marrow and organ function&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 75 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Patient has adequate liver function&#xD;
&#xD;
               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is&#xD;
                  liver metastasis)&#xD;
&#xD;
               -  Serum bilirubin ≤ 2 x ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No malabsorption or other gastrointestinal disorders affecting drug absorption.&#xD;
&#xD;
          -  No serious complications such as active gastrointestinal hemorrhage, perforation,&#xD;
             jaundice, gastrointestinal obstruction, non cancerous fever &gt; 38 ℃.&#xD;
&#xD;
          -  Expect good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has received previous treatment with EGFR inhibitors&#xD;
&#xD;
          -  Patient is currently receiving Phenytoin, rifampin, barbiturates, C Masi Bing&#xD;
&#xD;
          -  Known severe hypersensitivity to Icotinib or any of the excipients of this product&#xD;
&#xD;
          -  CNS metastases without radiotherapy and/or surgery&#xD;
&#xD;
          -  Patients with treated CNS metastases may participate in this trial,except for those&#xD;
             who must receive hormone therapy and those whose prior hormone therapy for CNS&#xD;
             metastases is less than 4 weeks&#xD;
&#xD;
          -  Evidence of clinically active Interstitial Lung Diseases&#xD;
&#xD;
          -  Severe systemic disease out of control such as unstable or uncompensated&#xD;
             respiratory,cardiac,liver,renal diseases&#xD;
&#xD;
          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study&#xD;
             enrollment, (with the exception of nonmelanoma skin cancer or cervical carcinoma in&#xD;
             situ&#xD;
&#xD;
          -  psychiatric illness that would prevent the patient from giving informed consent&#xD;
&#xD;
          -  Patient is concurrently using other approved or investigational antineoplastic agent&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yuhong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Yuhong, MD</last_name>
    <email>liyh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yuhong, MD</last_name>
      <email>liyh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Yuhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

